Company Description
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally.
The company offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH).
Its products include the FREEDOM60 and FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.
The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022.
KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.
| Country | United States |
| Founded | 1980 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 80 |
| CEO | Linda Tharby |
Contact Details
Address: 100 Corporate Drive Mahwah, New Jersey 07430 United States | |
| Phone | 845-469-2042 |
| Website | korumedical.com |
Stock Details
| Ticker Symbol | KRMD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000704440 |
| CUSIP Number | 759910102 |
| ISIN Number | US7599101026 |
| Employer ID | 13-3044880 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Linda M. Tharby | President, Chief Executive Officer and Director |
| Thomas Adams | Chief Financial Officer, Secretary and Treasurer |
| Christopher Pazdan | Chief Operating Officer |
| Rob Cannon | Interim Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2025 | 8-K | Current Report |
| May 7, 2025 | SCHEDULE 13G/A | Filing |
| May 7, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |
| Apr 21, 2025 | 144 | Filing |
| Apr 7, 2025 | 8-K | Current Report |
| Apr 4, 2025 | 8-K | Current Report |
| Apr 4, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 19, 2025 | 144 | Filing |
| Mar 19, 2025 | 144 | Filing |